Paper
0
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Authors
Meletios Dimopoulos,Albert Oriol
Hareth Nahi,Jesús Miguel,Nizar Bahlis,Saad Usmani,Neil Rabin,Robert Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung‐Soo Yoon,Dina Yehuda,Paul Richardson,Hartmut Goldschmidt,Donna Reece,Steen Lisby,Nushmia Khokhar,Lisa O’Rourke,Christopher Chiu,Xiang Qin,Mary Guckert,Tahamtan Ahmadi
+21 authors
,Philippe MoreauPublished
Oct 5, 2016
Show more
Save
Tip0
TipSave
Abstract
Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple myeloma.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.